San Francisco, CANCT03715933Now EnrollingIRB Ready

Ewing Sarcoma Clinical Trial in San Francisco, CA

Access cutting-edge ewing sarcoma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Inhibrx Biosciences, Inc

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access ewing sarcoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ewing sarcoma treatment provided free

Apply for This San Francisco Location

Check if you qualify for this ewing sarcoma clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Ewing Sarcoma Study in San Francisco

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Sponsor: Inhibrx Biosciences, Inc

Who Can Participate

Inclusion Criteria

Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less than 85 years of age for other tumors.
Part 3 combination therapy expansion tumor types:
Histologically confirmed Ewing sarcoma with a classical fusion: Patients with locally advanced or metastatic, unresectable, relapsed, or refractory disease who have received at least 1 but no more than 2 prior lines of systemic treatment with a preferred first line chemotherapy regimens.
Colorectal adenocarcinoma: Patients who have failed 1 (one) prior line of systemic therapy that did not include irinotecan.
Colorectal adenocarcinoma: Patients who have failed 2 but no more than 3 prior lines of systemic therapy and are FTD/TPI-naïve.
Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria.
Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1, or Karnofsky Performance Status score of ≥60, or Lansky Play-Performance Scale for Children score ≥60 (for patients less than 16 years).
Estimated life expectancy of at least 12 weeks.
Availability of archival tissue or fresh cancer biopsy are mandatory.

Exclusion Criteria

Prior treatment with or exposure to DR5 agonists.
Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment. Exceptions per protocol.
Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.
Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug.
Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years. Exceptions per protocol.
Prior or concurrent malignancies. Exceptions per protocol.
Hematologic malignancies.
Symptomatic active primary CNS tumors, leptomeningeal disease, and CNS metastases. Exceptions per protocol. Patients with any evidence or history of multiple sclerosis (MS) or other demyelinating disorders are excluded.
Chronic liver diseases including fatty liver. Exception: Patients \< 45 years old with fatty liver disease may be accepted as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.
Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.
Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
Known sensitivity or contraindications to the following drugs:
Ewing sarcoma: irinotecan or TMZ
colorectal adenocarcinoma: FU, leucovorin, irinotecan, bevacizumab or FTP/TPI
Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease less than 3 months prior to enrollment.
Acute, hemodynamically significant deep vein thrombosis or clinically significant pulmonary embolism not resolved or stable for at least 3 months prior to the start of study treatment.
Major surgery within 4 weeks prior to enrollment on this trial.
Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug.
Other exclusion criteria per protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT03715933) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ewing Sarcoma Treatment Options in San Francisco, CA

If you're searching for ewing sarcoma treatment options in San Francisco, CA, this clinical trial (NCT03715933) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ewing sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ewing sarcoma clinical trials near you to find additional studies recruiting in your area.

More Sarcoma Trials in San Francisco, CA

See all sarcoma clinical trials recruiting in San Francisco — not just this study.

Browse Sarcoma Trials in San Francisco →

Browse More Trials by Condition

Sarcoma TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA